Ok, I agree with that. What do you think will happen to ELTP's share price if they approve Sequestox with ADT labeling the same as that recommended for PFE by the adcom (i.e., ADT labeling for iv and nasal, but not oral)? That's the $100million question, I think, because my guess is that is exactly what is going to happen. As you indicate, they can't really approve a drug for oral ADT because there is no current technology that will prevent oral abuse of drugs (i.e., you cannot really prevent someone from taking five at a time). Thoughts?
News 
Market Data 
Discover 
